ES2334149T3 - Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. - Google Patents

Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. Download PDF

Info

Publication number
ES2334149T3
ES2334149T3 ES05706024T ES05706024T ES2334149T3 ES 2334149 T3 ES2334149 T3 ES 2334149T3 ES 05706024 T ES05706024 T ES 05706024T ES 05706024 T ES05706024 T ES 05706024T ES 2334149 T3 ES2334149 T3 ES 2334149T3
Authority
ES
Spain
Prior art keywords
vtmr
tenofovir
agents
breast cancer
adefovir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05706024T
Other languages
English (en)
Spanish (es)
Inventor
Tomas Cihlar
Janet L. Douglas
Craig S. Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2334149T3 publication Critical patent/ES2334149T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES05706024T 2004-01-21 2005-01-21 Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. Expired - Lifetime ES2334149T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
US538066P 2004-01-21

Publications (1)

Publication Number Publication Date
ES2334149T3 true ES2334149T3 (es) 2010-03-05

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05706024T Expired - Lifetime ES2334149T3 (es) 2004-01-21 2005-01-21 Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria.

Country Status (10)

Country Link
US (2) US20070281911A1 (enExample)
EP (1) EP1732569B1 (enExample)
JP (1) JP2007518815A (enExample)
AT (1) ATE445404T1 (enExample)
AU (1) AU2005209256B2 (enExample)
CA (1) CA2553455A1 (enExample)
DE (1) DE602005017131D1 (enExample)
ES (1) ES2334149T3 (enExample)
NZ (1) NZ548532A (enExample)
WO (1) WO2005072748A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
PL2020996T3 (pl) 2006-05-16 2012-04-30 Gilead Sciences Inc Sposób i kompozycje do leczenia chorób nowotworowych układu krwiotwórczego
EP2486407B1 (en) * 2009-10-05 2016-02-10 Ambergen Inc. A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
CA2856722C (en) 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
WO2020171225A1 (ja) * 2019-02-22 2020-08-27 一素 村田 ｍＴＯＲ阻害剤
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
WO2021003421A1 (en) * 2019-07-02 2021-01-07 Virago Vax Inc. Mammary tumor virus suppression
AU2023236711A1 (en) 2022-03-15 2024-10-03 Rome Therapeutics, Inc. Compounds and methods for treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038889D1 (de) * 1999-06-01 2008-06-26 Ochsner Med Found Alton Identifizierung eines neuartigen retrovirus welcher mit primärer leberzirrhose sowie autoimmunerkrankungen einhergeht
MXPA01013388A (es) * 1999-06-30 2002-07-02 Tulane University Medical Ct Retrovirus endogeno humano en cancer de pecho.
DK1301519T4 (da) * 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues

Also Published As

Publication number Publication date
US20050239753A1 (en) 2005-10-27
HK1099228A1 (en) 2007-08-10
US20070281911A1 (en) 2007-12-06
WO2005072748A1 (en) 2005-08-11
CA2553455A1 (en) 2005-08-11
AU2005209256A1 (en) 2005-08-11
AU2005209256B2 (en) 2010-11-18
DE602005017131D1 (de) 2009-11-26
EP1732569B1 (en) 2009-10-14
JP2007518815A (ja) 2007-07-12
ATE445404T1 (de) 2009-10-15
EP1732569A1 (en) 2006-12-20
NZ548532A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
ES2334149T3 (es) Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria.
ES2785034T3 (es) Métodos para el tratamiento de infecciones de virus de filoviridae
ES2918585T3 (es) Métodos para el tratamiento de infecciones por el virus Arenaviridae
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
BR112013001553A2 (pt) Métodos e compostos para tratar infecções por vírus paramyxoviridae
TR201906416T4 (tr) Hiv inhibitörü bileşiklerin fosfonat analogları.
ES2910049T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
EP4486746A1 (en) Compounds and methods for treatment of viral infections
US20200093841A1 (en) Broad Spectrum Antiviral and Methods of Use
US20220088042A1 (en) Combination therapy including sapc-dops for the treatment of pancreatic cancer
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
ES2969239T3 (es) Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
CN101959407A (zh) 4’-硫-2’-去氧核苷作为抗正痘病毒剂的用途
KR100632520B1 (ko) Β 형 간염 바이러스를 치료하기 위한 복합 요법
Morris-Natschke et al. Phospholipid analogs against HIV-1 infection and disease
ES2747073T3 (es) Combinación de RO5503781, capecitabina y oxaliplatino para el tratamiento del cáncer
WO2011046901A2 (en) Broad spectrum antiviral and methods of use
HK1099228B (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
HK1258795B (en) Methods for treating filoviridae virus infections
Mannhold et al. Antiviral Drug Strategies
HK1242569B (en) Methods for treating filoviridae virus infections
HK1242569A1 (en) Methods for treating filoviridae virus infections